In the last 5 years, the most cited articles were published by Ren et al. (2020), who reported that metformin, a classic hypoglycemic agent, produced renoprotective effects against diabetes via the AMPK/SIRT1-FoxO1 pathway. Here, SIRT1 is linked to diabetes mellitus.